NOBIVAC RL
NOBIVAC RL
Authorised
- Rabies virus, strain Pasteur RIV, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain 820K, Inactivated
Product identification
Medicine name:
НОБИВАК РЛ
NOBIVAC RL
Active substance:
- Rabies virus, strain Pasteur RIV, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain 820K, Inactivated
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Rabies virus, strain Pasteur RIV, Inactivated3.00/international unit(s)1.00Dose
-
Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated40.00/80% Protective Dose1.00Dose
-
Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain 820K, Inactivated40.00/80% Protective Dose1.00Dose
Pharmaceutical form:
-
Suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
- Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AL01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Bulgaria
Package description:
- Available only in Bulgarian
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
- INTERVET INTERNATIONAL B.V.
Responsible authority:
- BFSA
Authorisation number:
- 0022-1978-28.03.2013
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 12/06/2022
How useful was this page?:
